Evofem Biosciences, Inc.
Moat Score — Evofem Biosciences, Inc.
Total Moat Score
4 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | PHEXXI's FDA approval as the first and only hormone-free prescription contraceptive gel is a genuine regulatory and clinical differentiation, though Evofem's severe financial distress limits how much value that approval currently protects. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a financially distressed, OTCQB-listed company with outsourced manufacturing and a default notice from a key partner, Evofem has no cost advantage over larger, better-capitalized women's health competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | PHEXXI's unique hormone-free positioning offers some pricing differentiation versus hormonal alternatives, but competition from the newly over-the-counter Opill and reimbursement pressure on SOLOSEC from cheaper generics constrain real pricing power. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | This factor does not apply to Evofem's prescription pharmaceutical sales business. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Patients and prescribers can readily switch to any of numerous alternative contraceptive methods (IUDs, implants, pills, patches, or the OTC Opill), so Evofem benefits from minimal switching-cost lock-in. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | The contraceptive and women's sexual health market includes many established, well-funded competitors across hormonal, non-hormonal, and OTC categories, offering no natural barrier protecting Evofem's position. |